Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: A multicenter, randomized, double‐blind, phase III study in North America
- 28 August 2003
- journal article
- clinical trial
- Published by Wiley in Head & Neck
- Vol. 25 (9), 717-731
- https://doi.org/10.1002/hed.10261
Abstract
Background. The objective was to evaluate the efficacy and safety of a novel intratumoral cisplatin/epinephrine injectable gel (CDDP/epi gel) for local control and palliation of tumor‐related symptoms in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Patients and Methods. Eighty‐seven patients were randomly assigned to either CDDP/epi or placebo gel in this phase III, double‐blind study. Tumors were ≤20 cm3; most recurrences (88%) were in a previously irradiated field. The most symptomatic or threatening tumor was designated as the target tumor. Dose: 0.25 mL CDDP/epi gel/cm3 tumor volume. Treatments: ≤6 weekly intratumoral injections in an 8‐week period. Primary outcomes: target tumor response and symptom relief. Results. During the blinded phase, 34% (21 of 62) of patients achieved an objective response (CR or PR) in the target tumor treated with CDDP/epi gel vs 0% (0 of 24) treated with placebo gel (p < .001). Responses occurred within a median of four treatments (range, 2–6) and were durable (median, 95 days; range, 34–168+ days). More patients treated with CDDP/epi gel achieved palliative benefit than did those treated with placebo gel (37% vs 12%, p = .036). Most frequent side effects were local pain and local cutaneous reactions, which resolved over 3–12 weeks. Renal and hematologic toxicities were rare. Conclusions. This phase III trial showed that CDDP/epi gel significantly reduces tumor burden, palliates tumor‐related symptoms, and is an effective local treatment for recurrent tumors. © 2003 Wiley Periodicals, Inc. Head Neck 25: 717–731, 2003Keywords
This publication has 38 references indexed in Scilit:
- Heterogeneous Distribution of Tumor Blood Supply Affects the Response to Chemotherapy in Patients with Head and Neck CancerMicrocirculation, 2000
- Intratumoral cisplatin/epinephrine‐injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot studyOtolaryngology -- Head and Neck Surgery, 1998
- “Decadose” Effects of Cisplatin on Squamous Cell Carcinoma of the Upper Aerodigestive Tract. II. Clinical StudiesThe Laryngoscope, 1996
- “Decadose” Effects of Cisplatin on Squamous Cell Carcinoma of the Upper Aerodigestive Tract. I. Histoculture ExperimentsThe Laryngoscope, 1996
- Clinical and Immunopathological Results of a Phase II Study of Perilymphatically Injected Recombinant Interleukin-2 in Locally Far Advanced, Nonpretreated Head and Neck Squamous Cell CarcinomaJournal of Immunotherapy, 1991
- Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cellsEuropean Journal of Cancer and Clinical Oncology, 1989
- Ergebnisse der simultanen Radio-Polychemotherapie bei fortgeschrittenen inoperablen Kopf-Hals-KarzinomenLaryngo-Rhino-Otologie, 1988
- Topical administration of cisplatin in far-advanced squamous cell carcinoma of the head and neckEuropean Journal of Cancer and Clinical Oncology, 1986
- Topical Chemotherapy of Cutaneous Malignancy of the Head and NeckSouthern Medical Journal, 1969
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958